Aquestive Therapeutics, Inc. (AQST)
Nasdaq: AQST · Pharmaceutical Preparations · Warren, NJ · filing with the SEC since 2007
Filings
339 filings since 2017 beside 344 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 34 days after the quarter ended. The proxy statement was last filed Apr 24, 2026.
Filings a yearinsider forms included
7066717275847290
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 5 times in the last 36 months, the newest Sep 29, 2026.SEC letters: 6 in the last 36 months, the newest Apr 19, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 3, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Oct 19, 2026
8-K items 5.03, 9.01
Charter, bylaw or fiscal-year change · Current report
Oct 15, 2026
Sep 17, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Sep 14, 2026
Aug 11, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Aug 10, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
May 13, 2026
8-K items 1.01, 1.02, 2.02, 2.03, 3.02, 7.01, 9.01
Major agreement signed; Major agreement ended; Results released; New debt or obligation taken on; Shares sold without registration; Investor disclosure (Regulation FD) · Current report
May 12, 2026
Mar 20, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Mar 16, 2026
Mar 4, 2026
8-K items 1.01, 2.02, 3.02, 7.01, 9.01
Major agreement signed; Results released; Shares sold without registration; Investor disclosure (Regulation FD) · Current report
Mar 3, 2026
Nov 5, 2025
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
40 of 339 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.